This project will generate, characterize and provide aptamers that will be used in multiple projects for in vitro, cellular and in vivo applications. Aptamers have emerged as an alternative compound class providing high affinity binding and inhibition of biomolecules. The platform has successfully identified, characterized and applied aptamers and provided them to various groups within the CRC. The platform we will continue to provide individual subprojects with the required aptamers, fully characterized in terms of affinity and specificity. In addition, and in combination with the platform P02 'Recombinant adeno-associated- and lentiviral technologies’, we will construct and characterize recombinant viruses for the expression of aptamers in neurons and glia, which will make them also suitable for in vivo studies.
DFG Programme
Collaborative Research Centres
